AstraZeneca PLC
24 January 2006
Dealing by Directors
Companies Act 1985 Sections 324/329
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R
We hereby inform you that, on 23 January 2006, Dr H L Mogren, a Director of the
Company, ceased to have an interest in an option over 9,826 AstraZeneca PLC
Ordinary Shares of USD0.25 each following its expiry.
The option was originally granted to Dr Mogren in 1999 for a period of seven
years over shares in Astra AB under the Astra Shareholder Value Incentive Plan.
The option was subsequently converted into an option over Ordinary Shares in
AstraZeneca PLC in April 1999. The option has not been exercised by Dr Mogren
and has consequently expired on reaching the seventh anniversary of the date of
grant. Details of the option are as follows:-
Number of AstraZeneca shares over which Effective option Market price of AstraZeneca shares
option was held price per share when option expired
9,826 441.78SEK 356.50SEK
Following the expiry of this option, Dr Mogren holds options over 244,896
Ordinary Shares of AstraZeneca PLC.
G H R Musker
Company Secretary
24 January 2006
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.